METHODS: We performed a subgroup analysis of patients aged ≥65 years included in a previous 12-month multicenter study on adults. Treatment discontinuation, seizure frequency, and adverse events were recorded at 3, 6 and 12 months after PER introduction. Sub-analyses by early (≤1 previous ASM) or late PER add-on were also conducted.
RESULTS: The sample included 65 subjects (mean age: 75.7 ± 7.2 years), with mainly focal (73.8%) epilepsy. The mean PER daily dose was ≈4 mg during all follow-up. Retention rates at 3, 6, and 12 months were 90.5%, 89.6%, and 79.4%ly. The baseline median normalized per 28-day seizure number significantly decreased at 3-, 6- and 12-month visits. One year after PER introduction, the responder rate (≥50% reduction in baseline seizure frequency) was 89.7%, with a seizure freedom rate of 72.4%. Adverse events occurred in 22 (34.9%) patients with dizziness and irritability being the most frequent. No major differences between early (41 patients, 63.1%), and late add-on groups were observed.
CONCLUSIONS: Adjunctive PER was effective and well-tolerated when used as only add-on treatment in elderly people with epilepsy in clinical practice, thus representing a suitable therapeutic option in this age category.
方法:我们对先前12个月多中心成人研究中年龄≥65岁的患者进行了亚组分析。停止治疗,癫痫发作频率,并在引入PER后3,6和12个月记录不良事件.还进行了早期(≤1个先前的ASM)或晚期PER附加子分析。
结果:样本包括65名受试者(平均年龄:75.7±7.2岁),以局灶性癫痫为主(73.8%)。在所有随访期间,平均PER日剂量约为4mg。3、6和12个月的保留率为90.5%,89.6%,79.4%。基线中位数标准化每28天癫痫发作次数显着下降3,6个月和12个月的访问。PER引入一年后,应答率(基线发作频率降低≥50%)为89.7%,癫痫发作自由率为72.4%。不良事件发生在22例(34.9%)患者中,头晕和烦躁最常见。早期(41例患者,63.1%),并观察到后期添加组。
结论:在临床实践中,辅助PER仅用作老年癫痫患者的附加治疗时有效且耐受性良好,因此代表了该年龄段的合适治疗选择。